ELIMINATION OF GRAFT-VERSUS-HOST DISEASE BY IN-VITRO DEPLETION OF ALLOREACTIVE LYMPHOCYTES WITH A MONOCLONAL RAT ANTI-HUMAN LYMPHOCYTE ANTIBODY (CAMPATH-1)

Herman Waldmann(University of Cambridge), S Slavin(N. I. Lobachevsky State University of Nizhny Novgorod), Reuven Or(Hadassah Academic College), Gabriel Cividalli(Hadassah Academic College), Lola Weiss(Hadassah Academic College), A. Polliak(Hadassah Academic College), D Manor(Hadassah Academic College), Chaim Brautbar(Hadassah Academic College), S Samuel(Hadassah Academic College), G Hale(Union Bank of Switzerland), E. A. Rachmilewitz(Hadassah Academic College), Z Weshler(Hadassah Academic College)
The Lancet
September 1, 1984
10.1016/s0140-6736(84)92564-9
Cited by 424

Related Papers

Nonmyeloablative Stem Cell Transplantation and Cell Therapy as an Alternative to Conventional Bone Marrow Transplantation With Lethal Cytoreduction for the Treatment of Malignant and Nonmalignant Hematologic Diseases
|Blood|1998|1.9k
Nonmyeloablative Stem Cell Transplantation and Cell Therapy as an Alternative to Conventional Bone Marrow Transplantation With Lethal Cytoreduction for the Treatment of Malignant and Nonmalignant Hematologic Diseases
|Blood|1998|1.8k
Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease
|New England Journal of Medicine|2020|859
In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation
|Blood|2000|502
Disabling Immune Tolerance by Programmed Death-1 Blockade With Pidilizumab After Autologous Hematopoietic Stem-Cell Transplantation for Diffuse Large B-Cell Lymphoma: Results of an International Phase II Trial
|Journal of Clinical Oncology|2013|439